401 related articles for article (PubMed ID: 15032580)
1. CD40/CD154 interactions at the interface of tolerance and immunity.
Quezada SA; Jarvinen LZ; Lind EF; Noelle RJ
Annu Rev Immunol; 2004; 22():307-28. PubMed ID: 15032580
[TBL] [Abstract][Full Text] [Related]
2. CD40 and tolerance induction.
Karimi MH; Pourfathollah AA
Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):1-13. PubMed ID: 22427471
[TBL] [Abstract][Full Text] [Related]
3. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
Gao W; Demirci G; Strom TB; Li XC
Transplantation; 2003 Sep; 76(6):994-9. PubMed ID: 14508368
[TBL] [Abstract][Full Text] [Related]
4. Determinations of B cell fate in immunity and autoimmunity.
Noelle RJ; Erickson LD
Curr Dir Autoimmun; 2005; 8():1-24. PubMed ID: 15564715
[TBL] [Abstract][Full Text] [Related]
5. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.
Sun W; Wang Q; Zhang L; Liu Y; Zhang M; Wang C; Wang J; Cao X
Transplantation; 2003 Nov; 76(9):1351-9. PubMed ID: 14627915
[TBL] [Abstract][Full Text] [Related]
6. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
Shepherd DM; Kerkvliet NI
J Immunol; 1999 Sep; 163(5):2470-7. PubMed ID: 10452982
[TBL] [Abstract][Full Text] [Related]
7. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives.
Dejica DI; Manea EM
Roum Arch Microbiol Immunol; 2006; 65(1-2):66-74. PubMed ID: 17877113
[TBL] [Abstract][Full Text] [Related]
8. Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation.
Néron S; Nadeau PJ; Darveau A; Leblanc JF
Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):25-40. PubMed ID: 21234809
[TBL] [Abstract][Full Text] [Related]
9. Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization.
Xu H; Yan J; Huang Y; Chilton PM; Ding C; Schanie CL; Wang L; Ildstad ST
Blood; 2008 Mar; 111(6):3266-75. PubMed ID: 17827394
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
11. CD40 and CD154 in cell-mediated immunity.
Grewal IS; Flavell RA
Annu Rev Immunol; 1998; 16():111-35. PubMed ID: 9597126
[TBL] [Abstract][Full Text] [Related]
12. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance.
Jarvinen LZ; Blazar BR; Adeyi OA; Strom TB; Noelle RJ
Transplantation; 2003 Nov; 76(9):1375-9. PubMed ID: 14627918
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
Zhu ZX; Fan LY; Wang Q
Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells.
Albert ML; Jegathesan M; Darnell RB
Nat Immunol; 2001 Nov; 2(11):1010-7. PubMed ID: 11590405
[TBL] [Abstract][Full Text] [Related]
15. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection.
Denton MD; Reul RM; Dharnidharka VR; Fang JC; Ganz P; Briscoe DM
Pediatr Transplant; 1998 Feb; 2(1):6-15. PubMed ID: 10084754
[TBL] [Abstract][Full Text] [Related]
16. CD40 and its crucial role as a member of the TNFR family.
Vogel LA; Noelle RJ
Semin Immunol; 1998 Dec; 10(6):435-42. PubMed ID: 9826576
[TBL] [Abstract][Full Text] [Related]
17. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
18. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.
Batrla R; Linnebacher M; Rudy W; Stumm S; Wallwiener D; Gückel B
Cancer Res; 2002 Apr; 62(7):2052-7. PubMed ID: 11929824
[TBL] [Abstract][Full Text] [Related]
19. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling.
Jacquot S; Kobata T; Iwata S; Morimoto C; Schlossman SF
J Immunol; 1997 Sep; 159(6):2652-7. PubMed ID: 9300684
[TBL] [Abstract][Full Text] [Related]
20. LTβR and CD40: working together in dendritic cells to optimize immune responses.
Gommerman JL; Summers deLuca L
Immunol Rev; 2011 Nov; 244(1):85-98. PubMed ID: 22017433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
